Author/Authors :
Rachel R. Kroe، نويسنده , , Martha A. Baker، نويسنده , , Martha P. Brown، نويسنده , , Neil A. Farrow، نويسنده , , Elda Gautschi، نويسنده , , Jerry L. Hopkins، نويسنده , , Roger R. LaFrance، نويسنده , , Anthony Kronkaitis، نويسنده , , Dorothy Freeman، نويسنده , , David Thomson، نويسنده , , Gerald Nabozny، نويسنده , , Christine A. Grygon، نويسنده , , Mark E. Labadia، نويسنده ,
Abstract :
The glucocorticoid receptor (GR) is involved in the transcriptional regulation of genes associated with inflammation, glucose homeostasis, and bone turnover through the association with ligands, such as corticosteroids. GR-mediated gene transcription is regulated or fine-tuned via the recruitment of co-factors including coactivators and corepressors. Current therapeutic approaches to targeting GR aim to retain the beneficial anti-inflammatory activity of the corticosteroids while eliminating negative side effects. Towards achieving this goal the experiments discussed here reveal a mechanism of co-factor binding in the presence of either bound agonist or antagonist. The GR ligand binding domain (GR-LBD(F602S)), in the presence of agonist or antagonist, utilizes different modes of binding for coactivator versus corepressor. Coactivator binding to the co-effector binding pocket of GR-LBD(F602S) is driven both by favorable enthalpic and entropic interactions whereas corepressor binding to the same pocket is entropically driven. These data support the hypothesis that ligand-induced conformational changes dictate co-factor binding and subsequent trans-activation or trans-repression.
Keywords :
Dexamethasone , Glucocorticoid receptor , RU-486 , Isothermal titration calorimetry , analytical ultracentrifugation , Surface plasmon resonance